{"entity":{"id":"xcovery","kind":"company","name":"Xcovery","aka":["Xcovery Holdings, Inc."],"tldr":"Xcovery is the Florida company that developed ensartinib, an ALK inhibitor approved by the FDA in December 2024 for ALK-positive non-small-cell lung cancer, partnered with Betta Pharmaceuticals in China where it was approved first.","summary":"Xcovery Holdings, based in Palm Beach Gardens, Florida, developed ensartinib (Ensacove), a second-generation ALK inhibitor. Its Chinese partner Betta Pharmaceuticals won approval there in 2020, and the FDA approved ensartinib in December 2024 for ALK-positive locally advanced or metastatic non-small-cell lung cancer in patients not previously treated with an ALK inhibitor, on the eXalt3 trial against crizotinib. Company facts are from the official website and FDA approval records.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.xcovery.com/"},{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["ensartinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct02767804"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Palm Beach Gardens, FL","country":"US","companyType":"biotech","website":"https://www.xcovery.com/","stage":"growth","investors":[],"funding":[]},"route":"/companies/xcovery/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"ensartinib","kind":"drug","name":"Ensartinib","route":"/drugs/ensartinib/"}],"trial":[{"id":"nct05393466","kind":"trial","name":"BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct05393466/"},{"id":"nct02767804","kind":"trial","name":"eXalt3","route":"/trials/nct02767804/"}]}}